Home » Stocks » ADMS

Adamas Pharmaceuticals, Inc. (ADMS)

Stock Price: $4.83 USD 0.09 (1.90%)
Updated Mar 8, 2021 4:00 PM EST - Market closed
After-hours: $4.88 +0.05 (1.04%) Mar 8, 6:20 PM
Market Cap 220.00M
Revenue (ttm) 74.46M
Net Income (ttm) -57.40M
Shares Out 28.31M
EPS (ttm) -2.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $4.83
Previous Close $4.74
Change ($) 0.09
Change (%) 1.90%
Day's Open 4.75
Day's Range 4.66 - 4.98
Day's Volume 238,257
52-Week Range 1.90 - 9.15

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 3 days ago

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted two new employees r...

Zacks Investment Research - 6 days ago

Adamas (ADMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down ...

Business Wire - 1 week ago

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affecte...

Business Wire - 1 week ago

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affecte...

Business Wire - 1 week ago

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affecte...

Zacks Investment Research - 1 week ago

Adamas (ADMS) delivered earnings and revenue surprises of -20.76% and 1.01%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 1 week ago

Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 22.89% over the past year to ($0.64...

Business Wire - 1 week ago

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affecte...

Benzinga - 2 weeks ago

Adamas Pharmaceuticals (NASDAQ:ADMS) announces its next round of earnings this Tuesday, February 23. Here is Benzinga's everything-that-matters guide for this Tuesday's Q4 earnings announcement.

Business Wire - 2 weeks ago

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affecte...

Business Wire - 3 weeks ago

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report fourth quarter and year-end 2020 financial results on Tuesday, Feb...

Business Wire - 1 month ago

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affecte...

Business Wire - 1 month ago

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to peo...

GlobeNewsWire - 1 month ago

-- Total revenues expected to be $20.8 million for fourth quarter 2020  and $74.2 million for full year 2020 -- -- Product sales of GOCOVRI® expected to be $19.8 million for fourth quarter 202...

GlobeNewsWire - 2 months ago

EMERYVILLE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference ...

GlobeNewsWire - 2 months ago

Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER Acquisition Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER Acquisition

GlobeNewsWire - 2 months ago

EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference ...

GlobeNewsWire - 2 months ago

EMERYVILLE, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted tw...

GlobeNewsWire - 3 months ago

Amended terms will provide added flexibility to help drive the growth of the Company Amended terms will provide added flexibility to help drive the growth of the Company

GlobeNewsWire - 3 months ago

As part of this agreement Adamas will acquire the global rights to OSMOLEX ER® As part of this agreement Adamas will acquire the global rights to OSMOLEX ER®

GlobeNewsWire - 3 months ago

EMERYVILLE, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference ...

GlobeNewsWire - 3 months ago

EMERYVILLE, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference t...

GlobeNewsWire - 3 months ago

EMERYVILLE, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference ...

GlobeNewsWire - 3 months ago

EMERYVILLE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted th...

Seeking Alpha - 3 months ago

Adamas Pharmaceuticals recently reported its Q3 earnings with a slight beat on EPS and a slight miss on revenue. The company did report record product sales for GOCOVRI. Adamas looks to have f...

Seeking Alpha - 4 months ago

Adamas Pharmaceuticals' (ADMS) CEO Neil McFarlane on Q3 2020 Results -Earnings Call Transcript

Zacks Investment Research - 4 months ago

Adamas (ADMS) delivered earnings and revenue surprises of 16.00% and -5.60%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 4 months ago

Third quarter 2020 total revenues of $20.2 million, a 45% increase over third quarter 2019

GlobeNewsWire - 4 months ago

EMERYVILLE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference ...

Zacks Investment Research - 4 months ago

Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

EMERYVILLE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 third quarter financial results on Thursday,...

GlobeNewsWire - 5 months ago

EMERYVILLE, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference t...

GlobeNewsWire - 5 months ago

EMERYVILLE, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful differenc...

GlobeNewsWire - 6 months ago

EMERYVILLE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful differen...

GlobeNewsWire - 6 months ago

EMERYVILLE, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful differenc...

Seeking Alpha - 6 months ago

Adamas Pharmaceuticals recently reported their Q2 earnings with a strong beat on EPS and revenue. The market responded appropriately with the stock nearly doubling in subsequent trading days.

Seeking Alpha - 7 months ago

Adamas Pharmaceuticals' (ADMS) CEO Neil McFarlane on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 7 months ago

Second quarter 2020 GOCOVRI® product sales of $18.0 million, a 41% increase over second quarter 2019

Zacks Investment Research - 7 months ago

Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 7 months ago

EMERYVILLE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 second quarter financial results on Thursd...

GlobeNewsWire - 7 months ago

EMERYVILLE, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference...

Benzinga - 8 months ago

Adamas Pharmaceuticals (NASDAQ: ADMS) shares are trading lower on Thursday after the company reconfirmed it will not initiate further Phase 3 development in MSW.

GlobeNewsWire - 8 months ago

EMERYVILLE, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful differenc...

GlobeNewsWire - 9 months ago

EMERYVILLE, Calif., June 04, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful differenc...

GlobeNewsWire - 9 months ago

EMERYVILLE, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference...

Seeking Alpha - 9 months ago

Adamas Pharmaceuticals, Inc. (ADMS) CEO Neil McFarlane on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 10 months ago

First quarter 2020 GOCOVRI® product sales of $14.5 million, a 24% increase over first quarter 2019

Zacks Investment Research - 10 months ago

Adamas (ADMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 10 months ago

Adamas (ADMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 10 months ago

EMERYVILLE, Calif., April 10, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted...

About ADMS

Adamas Pharmaceuticals focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to tre... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Apr 10, 2014
CEO
Neil McFarlane
Employees
138
Stock Exchange
NASDAQ
Ticker Symbol
ADMS
Full Company Profile

Financial Performance

In 2020, ADMS's revenue was $74.46 million, an increase of 36.28% compared to the previous year's $54.64 million. Losses were -$57.40 million, -45.43% less than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for ADMS stock is "Buy." The 12-month stock price forecast is 10.44, which is an increase of 116.15% from the latest price.

Price Target
$10.44
(116.15% upside)
Analyst Consensus: Buy